VISENTIN, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 5.658
EU - Europa 811
AS - Asia 435
OC - Oceania 5
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.914
Nazione #
US - Stati Uniti d'America 5.653
IT - Italia 371
CN - Cina 338
SE - Svezia 102
FI - Finlandia 94
DE - Germania 79
GB - Regno Unito 72
VN - Vietnam 38
IN - India 34
IE - Irlanda 20
FR - Francia 18
NL - Olanda 13
UA - Ucraina 9
ES - Italia 6
JP - Giappone 6
PH - Filippine 6
CA - Canada 5
IL - Israele 5
PL - Polonia 5
AU - Australia 4
RO - Romania 4
RU - Federazione Russa 4
BG - Bulgaria 2
DK - Danimarca 2
EU - Europa 2
GR - Grecia 2
LV - Lettonia 2
PK - Pakistan 2
ZA - Sudafrica 2
AM - Armenia 1
CH - Svizzera 1
EE - Estonia 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SA - Arabia Saudita 1
TR - Turchia 1
TW - Taiwan 1
Totale 6.914
Città #
Fairfield 1.175
Ashburn 544
Woodbridge 517
Chandler 467
Seattle 455
Houston 435
Cambridge 411
Wilmington 303
Ann Arbor 283
Padova 147
San Diego 136
Beijing 107
Princeton 98
Medford 95
Helsinki 69
Des Moines 64
New York 53
Roxbury 44
Boardman 42
Dong Ket 38
Nanjing 37
Shenyang 23
Jinan 20
London 19
Pune 18
Milan 16
Dublin 14
Redwood City 12
Nanchang 11
Tianjin 11
Hebei 10
Rome 10
Hangzhou 8
Falls Church 7
Kharkiv 7
Lappeenranta 7
Paris 7
Taiyuan 7
Amsterdam 6
Cassano D'adda 6
Changsha 6
Fuzhou 6
Guangzhou 6
Phoenix 6
Taizhou 6
Washington 6
Haikou 5
Kilburn 5
Shanghai 5
Verona 5
Baltimore 4
Hefei 4
Jiaxing 4
Miami 4
Perugia 4
Pignone 4
Selvazzano Dentro 4
Zhengzhou 4
Baotou 3
Brendola 3
Caprino Veronese 3
Chicago 3
Chiswick 3
Kunming 3
North York 3
Nürnberg 3
Pagadian 3
Redmond 3
Rockville 3
Salsomaggiore Terme 3
Tokyo 3
Venice 3
'Omer 2
Acton 2
Aprilia 2
Arezzo 2
Belvedere Spinello 2
Bologna 2
Borås 2
Bothell 2
Buffalo 2
Cagayan de Oro 2
Cagliari 2
Cernusco sul Naviglio 2
Chak Two Hundred Ninety-five Gugera Branch 2
Copenhagen 2
Düsseldorf 2
Edinburgh 2
Forlì 2
Frankfurt am Main 2
Gorla Minore 2
Grand Junction 2
Halifax 2
Iasi 2
Islington 2
Isola della Scala 2
Istrana 2
Kochi 2
Las Vegas 2
Legnaro 2
Totale 5.925
Nome #
Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo 187
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL 181
Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells 159
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia 159
Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients 143
Role of miR-15a/miR-16-1 and TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia 142
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma 141
Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia 137
Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins 135
Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia 129
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 127
Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. 126
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia 123
Aberrant expression of CD10 and BCL6 in mantle cell lymphoma 123
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact 123
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases 121
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 120
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival 119
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. 119
Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies 118
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome 112
Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole. 111
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes 110
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment 108
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments 107
Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients 105
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia 105
Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy 104
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine 100
CX-4945, a selective inhibitor of casein kinase 2, synergizes with B cell receptor signaling inhibitors in inducing diffuse large B cell lymphoma cell death 97
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia 96
Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy 92
Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia 91
p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape 90
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases 88
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 87
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma 85
Peripheral nervous system involvement in lymphomas 85
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 85
A SCORING SYSTEM TO PREDICT THE RISK OF ATRIAL FIBRILLATION IN CHRONIC LYMPHOCYTIC LEUKEMIA 82
Increased Survival and Migration of CLL B-Cells in the Presence of Marrow Mesenchymal Stromal Cells: Novel Findings for Microenvironment-Targeted Therapies 78
Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature 78
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies 78
Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals 77
New responsibilities for aged kinases in B-lymphomas 74
CLL patients carrying 13q deletion show clinical heterogenity according to IGVH mutational status and CD38 expression 71
Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations 71
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 64
Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment 62
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma 62
Nerve Ultrasound abnormalities mirrors the course of VZV sensory-motor radiculoplexopathy 61
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells 61
Mechanisms of Nerve Damage in Neuropathies Associated with Hematological Diseases: Lesson from Nerve Biopsies 56
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real‐Life Campus CLL Study 55
B cells from Chronic Lymphocytic Leukemia undergo apoptosis following microtubule depolymerization by nocodazole 54
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients 53
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 53
EFFICACY OF IDELALISIB AND RITUXIMAB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA TREATED OUTSIDE OF CLINICAL TRIALS. A REPORT OF THE GIMEMA WORKING GROUP 51
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 50
A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib 49
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia 48
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials 46
Leukemic cell from B-CLL patients display heterogeneous response to the anti-apoptotic effect of mesenchymal stromal cells 45
CLL patients with low-risk cytogenetic abnormalities show clinical heterogeneity according to IGVH mutational status and CD38 expression 44
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) 41
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms 41
Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study 41
Expression and function of protein kinase CK2 in Hodgkin lymphoma 40
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy 39
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 36
Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study 35
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab 35
From pathogenesis to personalized treatments of neuropathies in hematological malignancies 33
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia 32
A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection 32
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 31
Increase of IgA during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia (CLL) patients 30
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study 30
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases 29
Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases 29
Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report 28
From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance 28
Anaemia during venetoclax ramp-up phase: Do not forget unusual causes 25
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 23
Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation 23
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 22
Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model 22
Response to "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients" 21
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience 21
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response 20
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia 18
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies 17
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies 16
[18F]FDG PET/CT and PET/MR in Patients with Adrenal Lymphoma: A Systematic Review of Literature and a Collection of Cases 15
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 15
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi 13
The added value of karyotype in predicting the need for therapy in chronic lymphocytic leukemia with 13q deletion 11
Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia 11
Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases? 11
Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital 10
Totale 7.037
Categoria #
all - tutte 27.930
article - articoli 27.699
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.629


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019400 0 0 0 0 0 0 0 19 10 66 153 152
2019/20201.406 121 62 11 84 121 78 108 167 156 230 171 97
2020/20211.781 123 110 128 213 52 35 70 139 220 332 216 143
2021/20221.558 77 142 129 122 145 88 86 143 140 41 132 313
2022/20231.074 214 85 32 127 152 106 15 77 113 18 96 39
2023/2024601 40 92 72 66 71 143 80 37 0 0 0 0
Totale 7.209